Cargando…
Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3)
BACKGROUND: Targeted lung denervation (TLD) is a bronchoscopically delivered ablation therapy that selectively interrupts pulmonary parasympathetic nerve signaling. The procedure has the potential to alter airway smooth muscle tone and reactivity, decrease mucous secretion, and reduce airway inflamm...
Autores principales: | Slebos, Dirk-Jan, Degano, Bruno, Valipour, Arschang, Shah, Pallav L., Deslée, Gaetan, Sciurba, Frank C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020591/ https://www.ncbi.nlm.nih.gov/pubmed/32054473 http://dx.doi.org/10.1186/s12890-020-1058-5 |
Ejemplares similares
-
Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
por: Christophe, Pison, et al.
Publicado: (2021) -
Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
por: Pison, Christophe, et al.
Publicado: (2021) -
Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2
por: Valipour, Arschang, et al.
Publicado: (2020) -
Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial
por: Slebos, Dirk-Jan, et al.
Publicado: (2019) -
Long-term safety of bilateral targeted lung denervation in patients with COPD
por: Valipour, Arschang, et al.
Publicado: (2018)